Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes

被引：0
|
作者：
Falchi, Lorenzo
Chihara, Dai
Bose, Prithviraj
Estrov, Zeev
Kantarjian, Hagop M.
Ravandi, Farhad
Verstovsek, Srdan
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4185
引用
收藏
页数：2
相关论文
共 26 条
  • [1] Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval
    Thomas, John William
    Shah, Mithun Vinod
    Vachhani, Pankit
    Jamy, Omer
    Go, Ronald S.
    Goyal, Gaurav
    BLOOD, 2020, 136
  • [2] Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
    Pemmaraju, Naveen
    Yu, Jingbo
    Parasuraman, Shreekant
    Paranagama, Dilan
    Kish, Jonathan
    Visaria, Jay
    Singhal, Mukul
    Verstovsek, Srdan
    Gerds, Aaron Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
    Mascarenhas, John
    Mehra, Maneesha
    He, Jianming
    Potluri, Ravi
    Loefgren, Christina
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 721 - 727
  • [4] Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX)
    Jain, Tania
    Katzen, Harvey
    Zeng, Jia
    Nguyen, Hiep
    Aton, Lindsay
    Qureshi, Parisa
    Fares, Marielle
    Shih, Yu-Hsuan
    Tang, Derek
    Vergara, Sara
    DeGutis, Irene S.
    Gerds, Aaron T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S379 - S379
  • [5] Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)
    Bartoszko, Justyna
    Panzarella, Tony
    McNamara, Caroline Jane
    Lau, Anthea
    Schimmer, Aaron D.
    Schuh, Andre C.
    Sibai, Hassan
    Yee, Karen W. L.
    Minden, Mark D.
    Devlin, Rebecca
    Gupta, Vikas
    BLOOD, 2016, 128 (22)
  • [6] Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST
    Komrokji, Rami S.
    Grunwald, Michael R.
    Braunstein, Evan
    Hamer-Maansson, J. E.
    Kalafut, Patricia
    Mascarenhas, John
    BLOOD, 2022, 140 : 6832 - 6834
  • [7] Ruxolitinib Retreatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
    Gerds, Aaron
    Yu, Jingbo
    Parasuraman, Shreekant
    Paranagama, Dilan
    Kish, Jonathan K.
    Visaria, Jay
    Singhal, Mukul
    Verstovsek, Srdan
    Pemmaraju, Naveen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S326
  • [8] LEUKEMIC TRANSFORMATION OF PRIMARY MYELOFIBROSIS - IMMUNOPHENOTYPE, GENOTYPE AND GROWTH-CHARACTERISTICS OF BLAST CELLS
    KIMURA, A
    KAWAISHI, K
    NAKATA, Y
    HYODO, H
    KURAMOTO, A
    SATOW, Y
    LEUKEMIA & LYMPHOMA, 1995, 19 (5-6) : 493 - 498
  • [9] Patient-reported outcomes (PRO) on the use of Ruxolitinib (RUX) in myelofibrosis (MF): data from the JAKoMo phase IV trial
    Koschmieder, S.
    Schulte, C.
    Reiser, M.
    Hansen, R.
    Koenigsmann, M.
    Geer, T.
    Groeschl, B.
    Grosser, S.
    Koehler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 68 - 68
  • [10] Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials
    Gupta, Vikas
    Verstovsek, Srdan
    Paquette, Ronald
    Gotlib, Jason R.
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Cervantes, Francisco
    Sun, William
    Gao, Jessy
    Langmuir, Peter
    Gopalakrishna, Prashanth
    Harrison, Claire N.
    BLOOD, 2016, 128 (22)
123